Cleo Diagnostics' Big Strides Against Ovarian Cancer
Cleo Diagnostics Chief Scientific Officer, Dr Andrew Stephens, joins Andrew Geoghegan of ausbiz to discuss the importance of the partnership with the University College London to access 2000 UKCTOCS biobank samples.
The significance of utilising samples from the largest ovarian cancer screening study aims to independently validate and accelerate Cleo's development of its Ovarian Cancer detection technology, along with strategic and financial value while supporting future regulatory submissions, including to the FDA and TGA.